Cellular targeting and subcellular distribution of HER-2 targeting boron liposomes

Chinese Journal of Radiation Mediation and Protection Pub Date : 2005-08-25 DOI:10.3760/CMA.J.ISSN.0254-5098.2005.04.004

Zheng Shu, W. Qi-chun, Shengru. Li, E. Kullberg, L. Gedda

{"title":"Cellular targeting and subcellular distribution of HER-2 targeting boron liposomes","authors":"Zheng Shu, W. Qi-chun, Shengru. Li, E. Kullberg, L. Gedda","doi":"10.3760/CMA.J.ISSN.0254-5098.2005.04.004","DOIUrl":null,"url":null,"abstract":"目的分析新制备的HER-2靶向硼脂质体在细胞靶向、滞留及细胞内分布等方面的特性,探讨该脂质体作为靶向给药系统用于硼中子俘获治疗研究的可能性.方法分别从靶向剂Trastuzumab、脂质体和装载的WSA 3个方面观察SK-BR-3细胞对125I-Trastuzumab-WSA-3H-脂质体的摄取与滞留.Trastuzumab标记了125I用伽玛计数器检测;脂质体标记了3H用液闪计数器检测;WSA用感应耦合等离子体-质谱仪检测.激光共聚焦显微镜观察WSA在细胞内的分布.结果最初8 h细胞对125I-Trastuzumab的摄取量快速增加,24 h后细胞内125I量反而有所下降.细胞对3H-脂质体的摄取随培养时间而增加,直到48 h也没有达到平台期.培养4、8及24 h,细胞含硼量分别达到55、78及132×10-6.细胞摄取125I-Trastuzumab-WSA-3H-脂质体后,在普通培养液中培养24和48 h,分别有90%、67%的WSA滞留在细胞内.激光共聚焦显微镜下显示大部分WSA位于细胞浆.结论细胞摄取量满意,WSA在细胞内滞留时间长,说明125I-Trastuzumab-WSA-3H-脂质体是一个很好的运载工具,有希望应用于硼中子俘获治疗研究.","PeriodicalId":374575,"journal":{"name":"Chinese Journal of Radiation Mediation and Protection","volume":"96 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2005-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Journal of Radiation Mediation and Protection","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.0254-5098.2005.04.004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

目的分析新制备的HER-2靶向硼脂质体在细胞靶向、滞留及细胞内分布等方面的特性,探讨该脂质体作为靶向给药系统用于硼中子俘获治疗研究的可能性.方法分别从靶向剂Trastuzumab、脂质体和装载的WSA 3个方面观察SK-BR-3细胞对125I-Trastuzumab-WSA-3H-脂质体的摄取与滞留.Trastuzumab标记了125I用伽玛计数器检测;脂质体标记了3H用液闪计数器检测;WSA用感应耦合等离子体-质谱仪检测.激光共聚焦显微镜观察WSA在细胞内的分布.结果最初8 h细胞对125I-Trastuzumab的摄取量快速增加,24 h后细胞内125I量反而有所下降.细胞对3H-脂质体的摄取随培养时间而增加,直到48 h也没有达到平台期.培养4、8及24 h,细胞含硼量分别达到55、78及132×10-6.细胞摄取125I-Trastuzumab-WSA-3H-脂质体后,在普通培养液中培养24和48 h,分别有90%、67%的WSA滞留在细胞内.激光共聚焦显微镜下显示大部分WSA位于细胞浆.结论细胞摄取量满意,WSA在细胞内滞留时间长,说明125I-Trastuzumab-WSA-3H-脂质体是一个很好的运载工具,有希望应用于硼中子俘获治疗研究.

查看原文